Bms-1166
Bms-1166 - Related Videos
09:56
Toxoplasma gondii Cyst Wall Formation in Activated Bone Marrow-derived Macrophages and Bradyzoite Conditions
0 Views •
Cited by 27 •
2010
Toxoplasma gondii converts to a cyst form in response to environmental stresses, which can be mimicked in tissue culture models. This video demonstrates techniques to examine cyst wall formation by activating bone marrow-derived macrophages or changing growth medium pH in fibroblast cells.
08:38
Engineering Skeletal Muscle Tissues from Murine Myoblast Progenitor Cells and Application of Electrical Stimulation
0 Views •
Cited by 40 •
2013
Engineered muscle tissue has great potential in regenerative medicine, as disease model and also as an alternative source for meat. Here we describe the engineering of a muscle construct, in this case from mouse myoblast progenitor cells, and the stimulation by electrical pulses.
11:08
Analysis of Cell Suspensions Isolated from Solid Tissues by Spectral Flow Cytometry
0 Views •
Cited by 4 •
2017
This article describes spectral cytometry, a new approach in flow cytometry that uses the shapes of emission spectra to distinguish fluorochromes. An algorithm replaces compensations and can treat auto-fluorescence as an independent parameter. This new approach allows for the proper analysis of cells isolated from solid organs.
FAQs
Dimerization provides a mechanistic link between compound binding and checkpoint disruption. By promoting association between PD-L1 molecules at the protein interface, BMS-1166 changes the availability of the surface involved in PD-1 recognition. This makes dimerization an experimentally useful feature for connecting molecular binding events with reduced checkpoint signaling in tumor-related immune studies.
The hydrophobic pocket serves as the binding site that positions BMS-1166 at the PD-L1 interface. Occupying this pocket is important because it supports the structural change associated with PD-L1 dimerization and limits productive PD-1 engagement. Studies of this interaction help clarify how a small molecule can modulate a protein-protein checkpoint interface.
BMS-1166 can help researchers separate checkpoint-mediated suppression from other influences on T-cell behavior. When the compound disrupts PD-1 engagement with PD-L1, investigators can examine resulting changes in T-cell responses within an experimental system. These observations provide mechanistic evidence about how the PD-1/PD-L1 interaction contributes to immune regulation in tumors.
As a chemical probe, BMS-1166 is applied to test the consequences of selectively modulating PD-L1 rather than treating the checkpoint pathway as an unexamined target. Researchers can use it to investigate PD-1/PD-L1 signaling, monitor T-cell responses, and evaluate whether experimental checkpoint blockade produces effects relevant to anticancer research.
Studies can assess whether disrupting the PD-1/PD-L1 interaction is accompanied by changes in T-cell activity or other measured immune responses in a cancer-research model. The compound therefore connects molecular mechanism to functional outcome. Interpreting those results can indicate how strongly checkpoint modulation contributes to the response observed under the tested conditions.
The comparison helps define what small-molecule PD-L1 modulation contributes beyond established antibody-based approaches. BMS-1166 offers a chemical strategy for probing the same checkpoint relationship and can be examined in experimental combination settings. Such work may clarify whether small-molecule modulation complements antibody immunotherapy and informs the design of investigational anticancer treatments.